Does DABIGATRAN Cause Hepatic lesion? 8 Reports in FDA Database
Lower Your Cholesterol — The Natural Way
The Oxidized Cholesterol Strategy: a science-backed plan for heart health.
According to the FDA Adverse Event Reporting System (FAERS), 8 reports of Hepatic lesion have been filed in association with DABIGATRAN. This represents 0.4% of all adverse event reports for DABIGATRAN.
8
Reports of Hepatic lesion with DABIGATRAN
0.4%
of all DABIGATRAN reports
0
Deaths
8
Hospitalizations
How Dangerous Is Hepatic lesion From DABIGATRAN?
Of the 8 reports, 8 (100.0%) required hospitalization.
Is Hepatic lesion Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for DABIGATRAN. However, 8 reports have been filed with the FAERS database.
What Other Side Effects Does DABIGATRAN Cause?
Gastrointestinal haemorrhage (210)
Hypotension (167)
Atrial fibrillation (150)
Drug interaction (143)
Haemorrhage (141)
Anaemia (131)
Dizziness (123)
Acute kidney injury (120)
Drug ineffective (118)
Fall (117)
What Other Drugs Cause Hepatic lesion?
OCTREOTIDE (296)
EVEROLIMUS (171)
RIBOCICLIB (144)
LETROZOLE (139)
CAPECITABINE (124)
ADALIMUMAB (123)
METHOTREXATE (108)
FULVESTRANT (107)
PALBOCICLIB (104)
CYCLOPHOSPHAMIDE (101)
Which DABIGATRAN Alternatives Have Lower Hepatic lesion Risk?
DABIGATRAN vs DABIGATRAN ETEXILATE
DABIGATRAN vs DABRAFENIB
DABIGATRAN vs DABRAFENIB\TRAMETINIB
DABIGATRAN vs DACARBAZINE
DABIGATRAN vs DACLATASVIR